ACOG has published two committee opinions on carrier screening. Committee Opinion 691 reviews the recommendations based on disorders. Committee Opinion 690 addresses the issues related to use of screening strategies such as expanded gene panel testing.
Key Highlights
Spinal Muscular Atrophy (SMA) has joined cystic fibrosis (CF) as a recommendation for all women who are pregnant or considering pregnancy
Hemoglobinopathies
Test all patients for CBC and RBC indices as part of antepartum care (ideally preconception)
Add Hgb electrophoresis if
Increased risk based on ethnicity: African, Middle Eastern, Southeast Asian, West Indian and Mediterranean ancestry
MCV is less than 80 fL with normal iron studies
Ashkenazi Jewish Testing (central and Eastern Europe descent)
Additional tests to ‘consider’ has been expanded to the following
Usher syndrome, Familial hyperinsulinism, Joubert and Maple syrup urine disease in addition to Bloom/Gaucher/Fanconi anemia/ML4/Neimann-Pick disease
Tay Sachs Disease
In addition to Ashkenazi Jews, offer if either partner is French-Canadian descent or Cajun
Screening can be performed using DNA-based testing (mutation analysis) or hexosaminidase enzyme in serum or leuckocytes (leukocyte only with oral contraceptives)
Enzyme testing picks up approximately 98% of carriers regardless of ethnicity
Mutation analysis is highly effective in at risk populations – detection rate is limited in other populations
Committee Opinion 690 reviews expanded carrier screening, including a discussion on counseling and what disorders should be included | Important summary statements include the following
Ethnic-specific, panethnic, and expanded carrier screening are acceptable strategies for prepregnancy and prenatal carrier screening. Each obstetrician–gynecologist or other health care provider or practice should establish a standard approach that is consistently offered to and discussed with each patient, ideally before pregnancy. After counseling, a patient may decline any or all carrier screening.
Expanded carrier screening does not replace previous risk-based screening recommendations. If obstetrician–gynecologists or other health care providers do not offer expanded carrier screening in their practice, screening recommendations for individual disorders should follow guidelines for carrier screening as outlined in Committee Opinion No. 691, Carrier Screening for Genetic Conditions.
Note: ACMG has published a document on preconception and prenatal carrier screening that includes a tiered approach to the selection of disorders | For the summary and links see ‘Related ObG Topics’ below)
ACOG and Universal Screening for Cystic Fibrosis – What You Need to Know
CLINICAL ACTIONS:
Genetic screening for Cystic Fibrosis (CF) has been recommended by ACOG and ACMG for over a decade.
Offer CF screening to all women of reproductive age, not just those in higher risk groups
Document previous CF screening results
Genetic testing does not need to be repeated in subsequent pregnancies if already on record
Expanded mutation panels beyond the ‘ACMG 23’ can be considered to increase sensitivity
DNA sequencing of the CFTR gene is not considered ‘appropriate’ for routine carrier screening and should be reserved for particular circumstances in conjunction with genetic counseling (see below in key points)
Refer for genetic counseling if both partners are CF carriers
CF is an autosomal recessive disorder and if both partners are affected, the risk to offspring is ¼ or 25%
SYNOPSIS:
Initially, prenatal screening for CF was limited to women from high risk groups, non-Hispanic whites and those of Ashkenazi Jewish background. However, as it becomes more difficult to identify specific racial groups and ethnicities, ACOG guidance is clear that all women of reproductive age should be screened to determine their carrier status. There are several genetic tests currently available that can sequence the entire CFTR gene, providing a clinical report for hundreds of CF disease causing mutations. While Committee Opinion 691 still mentions the original ACMG 23 mutation panel, expanded mutation panel analysis can be considered to help improve test sensitivity particularly among non-Caucasians.
KEY POINTS:
Full gene sequencing of the CFTR gene should be reserved for patients who meet the following criteria:
Personal history of CF
Family history of CF
Males with CBAVD
Newborns with positive newborn screening results when mutation panel testing is negative
Newborn screening for CF in newborns does not replace maternal screening
A negative newborn screen for CF cannot identify parental carriers
Second Trimester Echogenic Bowel: Important Ultrasound Finding with Varied Causes and Some Serious Implications
CLINICAL ACTIONS:
Fetal bowel can sometimes appear bright on prenatal ultrasound depending on the transducer used and machine settings. However, echogenic bowel in the fetus is not a significant finding unless the bowel appears as bright as bone (the brightness of the iliac wing can be used a reference). If the ultrasound report does confirm echogenic fetal bowel, further management should include
Aneuploidy screening
No previous aneuploidy screening
NIPS or quad screening
Negative aneuploidy screening
No further aneuploidy evaluation
Further work-up
Offer cystic fibrosis screening if not yet performed in current or prior pregnancy
Evaluate for cytomegalovirus (CMV) infection with IgG and IgM titers
Follow-up fetal growth scan in the third trimester to evaluate for growth restriction
If aneuploidy screening is positive, offer confirmatory diagnostic testing, referral for high-risk OB consultation and genetic counseling
SYNOPSIS:
Fetal echogenic bowel is present in up to 1.8% of second trimester ultrasound exams. It can be due to congenital cytomegalovirus infection, cystic fibrosis, intra-amniotic bleeding, fetal growth restriction, aneuploidy or gastrointestinal obstruction. Therefore, further work-up is warranted.
KEY POINTS:
Echogenic bowel is associated with aneuploidy (3 to 5%), the most common is Down syndrome (Trisomy 21)
If all identifiable causes are ruled out, fetal growth should be evaluated, as there is an association with fetal growth restriction
When isolated, normal fetal outcomes are likely. Pediatrics should be informed of the prenatal findings and work-up
Genetic Carrier Screening in Ashkenazi Jewish Patients
CLINICAL ACTIONS:
Offering carrier screening for various autosomal recessive conditions to patients of Ashkenazi Jewish or Central/Eastern European Jewish heritage has been a longstanding recommendation. ACOG describes a targeted panel. ACMG endorses panethnic prenatal carrier screening rather than direct larger panels toward specific high risk groups (see ‘Related ObG Topics’ below)
ACOG guidelines recommend, at a minimum, screening for the following disorders when offering genetic testing to those of Ashkenazi Jewish background
Tay Sachs Disease (1/30 carrier frequency)
Serum analysis in non-pregnant female, not taking oral contraceptives
Leukocyte analysis in pregnant female or female patient taking oral contraceptives
Cystic Fibrosis (1/29 carrier frequency)
Canavan disease (1/40 carrier frequency)
Familial Dysautonomia (1/32 carrier frequency)
ACOG includes the following disorders where screening ‘should be considered’
Mucolipidosis IV (1/127 carrier frequency)
Niemann-Pick disease type A (1/90 carrier frequency)
Fanconi anemia group C (1/90 carrier frequency)
Bloom syndrome (1/100 carrier frequency)
Gaucher disease type I (1/15 carrier frequency)
Familial hyperinsulinism (1/68 carrier frequency)
Glycogen storage disease type 1 (1/64 carrier frequency)
Joubert Syndrome (1/110 carrier frequency)
Maple syrup urine disease (1/97 carrier frequency)
Usher Syndrome (type 1F: 1/147 | type III; 1/120)
Additional Clinical Considerations
Simultaneous testing of both partners can be considered if the patient is pregnant and timing is a concern
If the patient is pregnant and only one member of the couple is Ashkenazi Jewish, it is best to test that individual first, if possible
One Jewish grandparent is sufficient for testing
If patient is unsure of background, always offer testing
Even if a patient reports being screening previously, without documentation, she needs to be screened again
SYNOPSIS:
A positive family history may not always be present for autosomal recessive conditions, even when there is a high carrier frequency in the Ashkenazi population. Therefore, carrier screening should be offered to those who identify as having Eastern European Jewish/Ashkenazi ancestry. Guidelines have tended toward genetic screening for conditions that have a high carrier frequency in this population. However, due to technological advances, more disorders have been added to genetic screening panels and while some diseases have relatively high carrier rates, others may be less frequent but are considered severe conditions.
KEY POINTS:
Informed consent for genetic testing at a minimum should include
A general description of the disorders
Some of these disorders may not always be severe
For example, cystic fibrosis can have relatively mild signs and symptoms
Residual risk for a disorder exists even if both partners have a negative carrier screening result, although less risk than prior to testing
A carrier of an autosomal recessive disorder is healthy but has a risk of passing the mutation to her offspring
Genetic counseling should be available for anyone who requests further information
When both partners are identified as carriers, there is a 25% chance that the fetus is carrying both mutations
Prenatal diagnosis with amniocentesis or chorionic villus sampling should be offered
Preimplantation Genetic Diagnosis (PGD) could be considered in couples when both are carriers for the same condition
Encourage patient to inform family members when they are confirmed carriers for any of the conditions for which they were tested
Testing for those of Jewish but non-Ashkenazi heritage
There are no guidelines specifically for Jews of Sephardic (descending from the Iberian/Spanish peninsula) or Mizrahi (Middle East, North Africa, Central Asia) heritage
Genetic testing panels that are comprehensive for Jewish individuals, regardless of area of origin, are now available and include over 90 disorders but most of these do not appear in the recommended ACOG list at this time
SMA variant in the Ashkenazi Jewish population
ACOG recommends that all women who are pregnant or considering pregnancy should be offered screening for SMA (see ‘Related ObG Topics’ below)
There are variants that tracks with silent carriers (i.e., found on chromosomes with duplications and not single-copy alleles) that can be incorporated into clinical carrier screening tests to improve residual risk estimates across all populations
Testing for one of these variants is available commercially in many laboratories and is especially effective in the Ashkenazi Jewish population to identify silent carriers
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan
You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site